{'52WeekChange': -0.26634985,
 'SandP52WeekChange': 0.0644362,
 'address1': '111 West Lemon Avenue',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 32.41,
 'askSize': 900,
 'averageDailyVolume10Day': 288300,
 'averageVolume': 540011,
 'averageVolume10days': 288300,
 'beta': 1.053221,
 'beta3Year': None,
 'bid': 32.41,
 'bidSize': 800,
 'bookValue': 10.403,
 'category': None,
 'circulatingSupply': None,
 'city': 'Monrovia',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 33.81,
 'dayLow': 32.28,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -18.805,
 'enterpriseToRevenue': 16.649,
 'enterpriseValue': 1284370176,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 32.006714,
 'fiftyTwoWeekHigh': 46.33,
 'fiftyTwoWeekLow': 19.35,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 51883476,
 'forwardEps': -1.53,
 'forwardPE': -21.18954,
 'fromCurrency': None,
 'fullTimeEmployees': 166,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.0979,
 'heldPercentInstitutions': 0.94617,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/xencor.com',
 'longBusinessSummary': 'Xencor, Inc., a clinical stage biopharmaceutical '
                        'company, focuses on the discovery and development of '
                        'engineered monoclonal antibody and other protein '
                        'therapeutics to treat severe and life threatening '
                        'diseases with unmet medical needs. It develops its '
                        'antibody product candidates to treat cancer and '
                        "autoimmune diseases. The company's product candidates "
                        'include XmAb5871, an immune inhibitor, which has been '
                        'completed Phase II clinical trial for the treatment '
                        'of autoimmune diseases; AIMab7195, which is in '
                        'development and commercialization stage. Its product '
                        'candidates also comprise XmAb14045, a bispecific '
                        'antibody which is in Phase I clinical trial for the '
                        'treatment of acute myeloid leukemia; plamotamab '
                        '(XmAb13676) that is in Phase I clinical trial to '
                        'treat B-cell malignancies; and XmAb18087, which is in '
                        'Phase I clinical trial for neuroendocrine tumors and '
                        'gastrointestinal stromal tumors. In addition, the '
                        'company offers Tafasitamab, an antibody drug '
                        'candidate for the treatment of patients with '
                        'relapsed/refractory diffuse; AMG424, a bispecific '
                        'antibody that targets CD38 and CD3, which is in Phase '
                        'I clinical trial for the treatment of various '
                        'myeloma; and AMG509, a bispecific antibody that is in '
                        'preclinical development stage to treat prostate '
                        'cancer. Further, it is developing bispecific '
                        'antibodies to treat various cancers, such as '
                        'XmAb20717, XmAb22841, and XmAb23104 which are in '
                        'preclinical Phase. Additionally, it offers XmAb24306, '
                        'initial cytokine candidate which is in Phase I '
                        'clinical trial. The company has collaboration and '
                        'license agreement with Novartis Institutes for '
                        'BioMedical Research, Inc.; MorphoSys Ag; Amgen Inc.; '
                        'and Catalent Pharma Solutions LLC. Xencor, Inc. was '
                        'founded in 1997 and is headquartered in Monrovia, '
                        'California.',
 'longName': 'Xencor, Inc.',
 'market': 'us_market',
 'marketCap': 1848095488,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_744102',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -61244000,
 'nextFiscalYearEnd': 1640908800,
 'open': 33.81,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '626 305 5900',
 'previousClose': 33.84,
 'priceHint': 2,
 'priceToBook': 3.1164086,
 'priceToSalesTrailing12Months': 23.955818,
 'profitMargins': -0.79387003,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 33.81,
 'regularMarketDayLow': 32.28,
 'regularMarketOpen': 33.81,
 'regularMarketPreviousClose': 33.84,
 'regularMarketPrice': 33.81,
 'regularMarketVolume': 201611,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 57004800,
 'sharesPercentSharesOut': 0.0673,
 'sharesShort': 3838306,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 3057730,
 'shortName': 'Xencor, Inc.',
 'shortPercentOfFloat': 0.1436,
 'shortRatio': 4.87,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'XNCR',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.08,
 'twoHundredDayAverage': 31.943094,
 'volume': 201611,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.xencor.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '91016'}